Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Changes in number of shares and votes in Egetis Therapeutics

EGTXSelskabsmeddelelse30.09.2026, 18.00
Download udgivelse

Stockholm, Sweden, September 30, 2026. The number of shares and votes in Egetis Therapeutics AB (publ) (“Egetis Therapeutics” or the “Company”) (Nasdaq Stockholm: EGTX) has changed in September as a result of the exercise of employee stock options granted under the 2022–2026 and 2023-2026 employee stock option programs.

The total number of shares in the Company is unchanged at 490,828,605, but the number of ordinary shares has increased by 18,338, from 464,947,224 to 464,965,562 and the number of C shares has decreased by 18,338, from 25,881,381 to 25,863,043. The total number of votes in the Company has increased by 16,504.2, from 467,535, 362.1 to 467,551,866.3.
The share capital is unchanged at approximately SEK 25,833,094.110797.

For further information, please contact:


Karl Hård, Head of Investor Relations & Business Development
+46 (0) 733 011 944
karl.hard@egetis.com 

About Egetis Therapeutics


Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.
The Company's lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and in the United States.
Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.
For more information, visit egetis.com and follow the Company on LinkedIn.

This information is information that Egetis Therapeutics is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-09-30 18:00 CEST.

Attachments


Changes in number of shares and votes in Egetis Therapeutics